Quantum Genomics (ALQGC) - A little company going after big indications

10:32 EDT 13 Jul 2018 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Quantum Genomics: Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Its lead programme, firibastat (QGC001), is in a 250-patient Phase IIb study in hypertensive overweight patients with patient dosing expected to be completed by the end of 2018 and data in Q119. Another Phase IIb in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI) is expected to launch by the end of 2018 with results due in H220.
ISIN: FR0011648971

Original Article: Quantum Genomics (ALQGC) - A little company going after big indications


More From BioPortfolio on "Quantum Genomics (ALQGC) - A little company going after big indications"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...